Journal article
Plasmodium vivax controlled human malaria infection - Progress and prospects.
- Abstract:
- Modern controlled human malaria infection (CHMI) clinical trials have almost entirely focussed on Plasmodium falciparum, providing a highly informative means to investigate host-pathogen interactions as well as assess potential new prophylactic and therapeutic interventions. However, in recent years, there has been renewed interest in Plasmodium vivax, with CHMI models developed by groups in Colombia, the USA and Australia. This review summarizes the published experiences, and examines the advantages and disadvantages of the different models that initiate infection either by mosquito-bite or using a blood-stage inoculum. As for P. falciparum, CHMI studies with P. vivax will provide a platform for early proof-of-concept testing of drugs and vaccines, accelerating the development of novel interventions.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.3MB, Terms of use)
-
- Publisher copy:
- 10.1016/j.pt.2016.11.001
Authors
- Publisher:
- Elsevier
- Journal:
- Trends in Parasitology More from this journal
- Volume:
- 33
- Issue:
- 2
- Pages:
- 141-150
- Publication date:
- 2016-12-10
- Acceptance date:
- 2016-11-04
- DOI:
- ISSN:
-
1471-5007
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:666113
- UUID:
-
uuid:9a6653a9-3c05-4dd0-9cff-21b8a355f7c9
- Local pid:
-
pubs:666113
- Source identifiers:
-
666113
- Deposit date:
-
2017-01-10
- ARK identifier:
Terms of use
- Copyright holder:
- Draper et al
- Copyright date:
- 2016
- Notes:
- © 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record